Pruritus - Pipeline Review, H2 2015

Published: November 2015
No. of Pages: 111
   

Global Markets Direct’s, ‘Pruritus - Pipeline Review, H2 2015’, provides an overview of the Pruritus’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pruritus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pruritus
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pruritus and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pruritus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pruritus pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pruritus
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Pruritus - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Pruritus Overview 9
Therapeutics Development 10
Pipeline Products for Pruritus - Overview 10
Pipeline Products for Pruritus - Comparative Analysis 11
Pruritus - Therapeutics under Development by Companies 12
Pruritus - Therapeutics under Investigation by Universities/Institutes 14
Pruritus - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Pruritus - Products under Development by Companies 18
Pruritus - Products under Investigation by Universities/Institutes 20
Pruritus - Companies Involved in Therapeutics Development 21
AlbireoPharma 21
Amorepacific Corporation 22
Cara Therapeutics, Inc. 23
Chugai Pharmaceutical Co., Ltd. 24
Creabilis SA 25
ELORAC, Inc. 26
FAES Farma SA 27
GlaxoSmithKline Plc 28
Helsinn Healthcare S.A. 29
Hydra Biosciences, Inc. 30
LEO Pharma A/S 31
Merck & Co., Inc. 32
NeRRe Therapeutics Ltd 33
Nippon Shinyaku Co., Ltd. 34
Phosphagenics Limited 35
RDD Pharma Ltd. 36
Shionogi & Co., Ltd. 37
Tioga Pharmaceuticals, Inc. 38
Trevi Therapeutics, Inc. 39
Vanda Pharmaceuticals Inc. 40
Pruritus - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
A-4250 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
aprepitant - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
asimadoline - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ASN-008 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
bilastine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
C-745 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
C-746 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
CR-845 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CT-327 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
CT-340 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
desloratadine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
GSK-2330672 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
lidocaine hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
nalbuphine hydrochloride ER - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
naloxone hydrochloride - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
nemolizumab - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
netupitant - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
NS-141 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
orvepitant maleate - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
PAC-14028 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Peptides to Target TRPV1 for Pain and Itch - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
RDD-1609 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
serlopitant - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecule to Agonize CB2 for Pruritus - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecules to Block NaV1.7 Channel for Pain and Pruritus - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecules to Inhibit Mas-Related G-Protein Coupled Receptor for Pruritus - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
tradipitant - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Pruritus - Recent Pipeline Updates 88
Pruritus - Dormant Projects 101
Pruritus - Discontinued Products 102
Pruritus - Product Development Milestones 103
Featured News & Press Releases 103
Oct 26, 2015: Cara Therapeutics to Present at 2nd Human Abuse Liability & Abuse-Deterrent Formulations Conference 103
Sep 09, 2015: Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative Pain 103
Jun 11, 2015: Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis 103
May 12, 2015: Cara Therapeutics provides update on its Phase 3 Program for I.V. CR845 104
Apr 15, 2015: Cara Therapeutics to Present at 3rd Conference on the Therapeutic Potential of Kappa Opioids 105
Mar 19, 2015: Creabilis’ CT327 Phase 2b Data Published in Acta Dermato-Venereologica, Strengthens Scientific Advisory Board 106
Mar 04, 2015: Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 106
Jan 12, 2015: Creabilis Receives Positive Feedback on CT327 from US FDA, Providing Clear Path to Registration 108
Dec 17, 2014: Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients 108
Dec 17, 2014: Velocity Pharmaceutical Development and Tigercat Pharma Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 109
Appendix 110
Methodology 110
Coverage 110
Secondary Research 110
Primary Research 110
Expert Panel Validation 110
Contact Us 110
Disclaimer 111

List of Tables

Number of Products under Development for Pruritus, H2 2015 10
Number of Products under Development for Pruritus - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 14
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Development by Companies, H2 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2015 20
Pruritus - Pipeline by AlbireoPharma, H2 2015 21
Pruritus - Pipeline by Amorepacific Corporation, H2 2015 22
Pruritus - Pipeline by Cara Therapeutics, Inc., H2 2015 23
Pruritus - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2015 24
Pruritus - Pipeline by Creabilis SA, H2 2015 25
Pruritus - Pipeline by ELORAC, Inc., H2 2015 26
Pruritus - Pipeline by FAES Farma SA, H2 2015 27
Pruritus - Pipeline by GlaxoSmithKline Plc, H2 2015 28
Pruritus - Pipeline by Helsinn Healthcare S.A., H2 2015 29
Pruritus - Pipeline by Hydra Biosciences, Inc., H2 2015 30
Pruritus - Pipeline by LEO Pharma A/S, H2 2015 31
Pruritus - Pipeline by Merck & Co., Inc., H2 2015 32
Pruritus - Pipeline by NeRRe Therapeutics Ltd, H2 2015 33
Pruritus - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015 34
Pruritus - Pipeline by Phosphagenics Limited, H2 2015 35
Pruritus - Pipeline by RDD Pharma Ltd., H2 2015 36
Pruritus - Pipeline by Shionogi & Co., Ltd., H2 2015 37
Pruritus - Pipeline by Tioga Pharmaceuticals, Inc., H2 2015 38
Pruritus - Pipeline by Trevi Therapeutics, Inc., H2 2015 39
Pruritus - Pipeline by Vanda Pharmaceuticals Inc., H2 2015 40
Assessment by Monotherapy Products, H2 2015 41
Number of Products by Stage and Target, H2 2015 43
Number of Products by Stage and Mechanism of Action, H2 2015 45
Number of Products by Stage and Route of Administration, H2 2015 47
Number of Products by Stage and Molecule Type, H2 2015 49
Pruritus Therapeutics - Recent Pipeline Updates, H2 2015 88
Pruritus - Dormant Projects, H2 2015 101
Pruritus - Discontinued Products, H2 2015 102

List of Figures

Number of Products under Development for Pruritus, H2 2015 10
Number of Products under Development for Pruritus - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 14
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Products, H2 2015 17
Assessment by Monotherapy Products, H2 2015 41
Number of Products by Top 10 Targets, H2 2015 42
Number of Products by Stage and Top 10 Targets, H2 2015 42
Number of Products by Top 10 Mechanism of Actions, H2 2015 44
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 44
Number of Products by Top 10 Routes of Administration, H2 2015 46
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 46
Number of Products by Top 10 Molecule Types, H2 2015 48
Number of Products by Stage and Top 10 Molecule Types, H2 2015 48

Published By: Global Markets Direct
Product Code: Global Markets Direct13705


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we´┐Żll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: